Last updated: July 31, 2026
Diethylstilbestrol (DES) is a legacy synthetic estrogen with no active branded pharmaceutical market in the United States, no meaningful new-drug development pipeline, and no remaining composition-of-matter exclusivity. Current activity is concentrated in epidemiologic follow-up of people exposed during pregnancy, limited country-specific clinical use, hospital compounding, and historical safety research. Commercial growth prospects are negligible. Demand is expected to remain low and fragmented through 2030.
What is the current clinical-trial status of diethylstilbestrol?
No active therapeutic development program is driving commercial investment in DES. Current research primarily examines the long-term effects of prenatal exposure rather than testing DES as a new treatment.
Current research areas
| Research area |
Current status |
Commercial relevance |
| Prenatal DES exposure |
Long-term observational follow-up of exposed mothers and offspring |
Supports safety surveillance and epidemiology |
| Cancer risk |
Studies of clear-cell adenocarcinoma, breast cancer, reproductive cancers and other outcomes |
No direct product opportunity |
| Reproductive health |
Research on fertility, pregnancy complications and structural abnormalities |
No new DES indication |
| Therapeutic oncology |
Historical use in prostate and breast cancer |
Superseded by newer endocrine and androgen-deprivation therapies |
| Menopausal or estrogen therapy |
Historical use only |
Replaced by safer and more standardized products |
The National Cancer Institute continues to track health outcomes among people exposed to DES in utero and their mothers through the DES Follow-up Study. The study has assessed reproductive outcomes, cancer incidence, cardiovascular effects and other long-term endpoints. Its purpose is observational surveillance, not drug development (National Cancer Institute, n.d.-a).
The Centers for Disease Control and Prevention identifies prenatal DES exposure as associated with clear-cell adenocarcinoma of the vagina and cervix, reproductive-tract abnormalities, infertility, pregnancy complications and certain other health outcomes (Centers for Disease Control and Prevention, n.d.).
Are any Phase 2 or Phase 3 DES trials recruiting?
There is no commercially relevant late-stage DES program. DES is not a modern investigational candidate, and its historical indications have been displaced by better-characterized therapies.
Clinical use, where it persists, is generally based on legacy medical practice, country-specific prescribing, or specialist and compounded supply rather than a contemporary clinical-trial strategy. DES is not positioned for a conventional FDA approval expansion.
What are the FDA regulatory and Orange Book statuses of diethylstilbestrol?
DES has no active U.S. regulatory profile comparable to a currently marketed branded drug.
FDA status
DES was widely used in the United States until evidence linked prenatal exposure to reproductive abnormalities and clear-cell adenocarcinoma. The FDA stated in 1971 that DES should not be used in pregnant women because it was ineffective for preventing miscarriage and posed risks to the fetus (U.S. Food and Drug Administration, 1971).
FDA-approved DES products historically included tablets and other dosage forms for indications such as advanced breast cancer and prostate cancer. Those uses have largely disappeared from routine U.S. practice. Current availability may involve discontinued products, foreign supply, or pharmacy compounding rather than an active, broadly marketed FDA-approved product.
Orange Book listing
The FDA Orange Book is intended to identify approved drug products and patent or exclusivity information associated with listed products. DES does not have a significant active Orange Book patent or exclusivity position comparable to modern branded medicines (U.S. Food and Drug Administration, n.d.-a).
| Regulatory factor |
DES position |
| Active U.S. branded product |
No significant active branded market |
| New chemical entity exclusivity |
Expired or not relevant |
| Pediatric exclusivity |
None of commercial importance |
| Orphan exclusivity |
None identified as a current market driver |
| Patent-term extension |
None relevant to the legacy molecule |
| Orange Book patent barrier |
No meaningful active barrier |
| Current FDA development pathway |
No visible commercial development pathway |
DES should not be analyzed as a branded product approaching loss of exclusivity. The molecule lost practical exclusivity decades ago. The primary regulatory issue is safety and availability, not patent protection.
What patents protect diethylstilbestrol?
No active composition-of-matter patent should be expected to protect DES in the United States or other major pharmaceutical markets.
DES was first synthesized in the 1930s and entered commercial medical use before the modern patent-term framework. Any historical composition, formulation and manufacturing patents would have expired many decades ago. Current commercial barriers therefore arise from regulatory compliance, sourcing, quality control and limited demand rather than intellectual property.
Patent-estate assessment
| Patent category |
Status |
Risk to entrants |
| Composition of matter |
Expired |
None |
| Salt or polymorph |
No material modern estate |
Low |
| Oral tablet formulation |
Historical rights expired |
None |
| Injectable formulation |
Historical rights expired or commercially inactive |
Low |
| Method of use |
Historical claims expired; modern use claims unlikely to support market exclusivity |
Low |
| Manufacturing process |
Historical claims expired |
Low |
| Drug-device combination |
Not material for DES |
None |
| Data exclusivity |
Expired or unavailable as a practical barrier |
None |
How strong is the DES patent estate?
The patent estate is commercially exhausted. A manufacturer could face quality, regulatory and supply-chain requirements, but not a meaningful patent blocking position. A new formulation could theoretically generate new patent claims, but any such strategy would need to overcome weak clinical demand, known safety concerns and competition from established alternatives.
Are there Paragraph IV challenges involving diethylstilbestrol?
No material current Paragraph IV litigation is associated with DES.
Paragraph IV litigation generally arises when a generic applicant seeks approval for a listed branded drug while challenging Orange Book patents. DES lacks an active branded market and a meaningful active patent estate, so the normal ANDA litigation structure is not commercially relevant.
Generic entry risk
Generic entry risk is technically high but economically unimportant. The molecule is old, inexpensive and chemically simple. The limiting factor is not the ability to manufacture DES. The limiting factors are:
- Low and geographically fragmented demand.
- Limited physician use.
- Safety concerns associated with prenatal exposure.
- Availability of more modern treatments.
- Uncertain commercial scale for active pharmaceutical ingredient supply.
- Potential need for compounding or country-specific regulatory pathways.
A new generic supplier would likely compete for a narrow specialist market rather than displace a large branded product.
What formulations are protected by diethylstilbestrol patents?
No commercially important active formulation patent is expected to protect the conventional DES dosage forms.
Historical dosage forms
DES has been used in or supplied as:
- Oral tablets.
- Injectable preparations.
- Compounded capsules or oral liquids.
- Historical vaginal or local estrogen formulations.
- Veterinary formulations in certain historical markets.
The most commercially relevant legacy form was the oral tablet. Modern formulation innovation is limited because DES has no clear product differentiation advantage over newer estrogenic, endocrine or oncology therapies.
A formulation containing DES could be patentable if it introduced a genuinely novel and non-obvious technical feature. That would not revive the old molecule's expired basic patent rights. It would create, at most, a narrow formulation position around a new product.
What medical uses remain for diethylstilbestrol?
DES has historical or limited specialist use in hormone-sensitive cancers, but its role has been substantially replaced.
Historical oncology use
DES was used for:
- Advanced prostate cancer.
- Advanced breast cancer.
- Palliative estrogen therapy.
Current prostate-cancer treatment relies primarily on androgen-deprivation therapy, androgen-receptor pathway inhibitors, chemotherapy, radiopharmaceuticals and other modern approaches. Current breast-cancer treatment relies on selective estrogen-receptor modulators, aromatase inhibitors, endocrine combinations, targeted agents and chemotherapy.
DES may retain occasional use where cost, availability or local practice influences prescribing. Those uses do not create a strong development market.
Pregnancy-related use
DES is not an accepted treatment for preventing miscarriage. FDA warnings and subsequent evidence ended its use for this purpose in the United States (U.S. Food and Drug Administration, 1971).
Prenatal exposure consequences
Prenatal exposure is the principal modern clinical relevance of DES. Exposed individuals may require targeted gynecologic, reproductive and cancer surveillance based on their exposure history and clinical findings. The CDC and NCI remain major sources of information on DES-related health effects (Centers for Disease Control and Prevention, n.d.; National Cancer Institute, n.d.-a).
Which companies are challenging or commercializing diethylstilbestrol?
There is no meaningful current innovator-versus-generic competitive landscape for DES in the United States.
Competitive structure
| Competitor group |
Position |
| Large pharmaceutical companies |
No visible strategic investment |
| Generic manufacturers |
Limited, fragmented or discontinued participation |
| Compounding pharmacies |
Potential source for niche demand |
| Specialty suppliers |
May serve country-specific or institutional markets |
| Veterinary suppliers |
Historical and jurisdiction-dependent activity |
| Modern oncology companies |
Compete indirectly through superior therapies |
The market is more likely to be supplied by small generic manufacturers, specialty distributors or compounding pharmacies than by multinational pharmaceutical companies.
What licensing deals involve diethylstilbestrol?
No material recent licensing transactions are associated with DES as an active growth asset.
Licensing value is constrained by:
- Expired core intellectual property.
- Lack of regulatory exclusivity.
- Known safety liabilities.
- Small therapeutic demand.
- Abundant substitute treatments.
- Limited potential for premium pricing.
Any transaction would more likely involve a portfolio of legacy products, regional distribution rights, or a compounding and supply arrangement. A standalone DES licensing deal would have limited strategic rationale.
What patent litigation and settlement agreements affect DES?
No significant current patent litigation or generic settlement agreement is associated with DES.
Historical litigation centered on personal injury, medical liability and prenatal exposure rather than modern pharmaceutical patent disputes. DES litigation has included claims involving manufacturers, physicians and alleged exposure-related injuries. These matters are distinct from Orange Book patent litigation and do not create a current commercial exclusivity framework.
What is the diethylstilbestrol market size and forecast?
DES has no transparent, globally reported commercial market comparable to active oncology or hormone-therapy drugs. Public market databases generally do not provide reliable standalone revenue estimates because sales are dispersed across discontinued products, generic channels, hospital pharmacies, compounding pharmacies and country-specific suppliers.
Market assessment
| Metric |
Assessment |
| Global commercial scale |
Very small relative to modern endocrine therapies |
| U.S. branded revenue |
Effectively absent |
| Primary demand |
Legacy or specialist use |
| Pricing power |
Low |
| Market concentration |
Fragmented |
| Growth driver |
None identified |
| Main risk |
Further discontinuation and supply contraction |
| Forecast direction through 2030 |
Flat to declining |
Revenue exposure
For pharmaceutical companies, direct revenue exposure to DES is likely immaterial. The larger economic exposure relates to substitute therapies that displaced DES, including:
- Androgen-deprivation medicines.
- Androgen-receptor inhibitors.
- Aromatase inhibitors.
- Selective estrogen-receptor modulators.
- Other endocrine and targeted oncology drugs.
A DES-related supply interruption could affect a small number of patients or institutions, but it would not materially alter the broader oncology or hormone-therapy market.
How does DES compare with modern endocrine therapies?
DES is disadvantaged on safety, evidence, tolerability, commercial support and treatment flexibility.
| Attribute |
Diethylstilbestrol |
Modern endocrine therapies |
| Regulatory status |
Legacy and jurisdiction-dependent |
Active approvals and guideline support |
| Patent position |
Expired |
Often protected by formulation, method or combination patents |
| Clinical evidence |
Historical and limited for current practice |
Contemporary randomized and real-world evidence |
| Safety profile |
Significant historical concerns |
Better characterized and indication-specific |
| Supply |
Fragmented |
Established commercial channels |
| Pricing |
Low |
Ranges from generic pricing to high specialty pricing |
| Development activity |
Minimal |
Active pipeline |
| Market outlook |
Declining or stable at a very low base |
Indication-dependent growth |
What generic launch scenarios exist for diethylstilbestrol?
A conventional generic launch would be feasible only in a narrow market.
Likely scenarios
Specialty generic launch: A manufacturer supplies oral DES tablets for a limited oncology or endocrine indication in a jurisdiction where demand persists. The product competes on availability and price.
Compounded supply: Pharmacies prepare capsules, liquids or other dosage forms for individual patients where commercial products are unavailable. This route is subject to local compounding and quality rules.
Regional re-entry: A distributor or small manufacturer reintroduces DES in a country with established clinical demand. The commercial opportunity remains limited because the molecule has no meaningful exclusivity.
Discontinuation scenario: A manufacturer exits because demand is too low to support validated production, regulatory maintenance or active ingredient procurement. This is the principal supply risk.
What manufacturing and geographic barriers affect DES?
Manufacturing technology is mature, and no technically difficult synthesis barrier is expected. The practical barriers are regulatory and commercial.
Geographic coverage
Availability varies by jurisdiction. DES may be unavailable, discontinued or restricted in one market while obtainable through specialty or compounding channels in another. The United States has particularly strong safety concerns because of the history of prenatal exposure and the absence of a meaningful mainstream indication.
Manufacturers must address:
- Current good manufacturing practice compliance.
- Active ingredient qualification.
- Impurity and stability specifications.
- Labeling and pharmacovigilance.
- Country-specific approval status.
- Controlled distribution or specialist prescribing requirements where applicable.
Geographic fragmentation raises fixed costs and reduces the attractiveness of a multinational launch.
When does diethylstilbestrol lose exclusivity?
DES lost practical exclusivity many decades ago. There is no commercially relevant future patent-expiration date comparable to a modern branded medicine's loss-of-exclusivity event.
| Exclusivity type |
Expected status |
| Core molecule |
Expired |
| Historical formulations |
Expired |
| Historical uses |
Expired |
| Regulatory exclusivity |
Expired or not applicable |
| Current blocking patents |
None of material commercial significance |
| Future generic entry |
Legally feasible, commercially limited |
Key Takeaways
- DES has no meaningful active U.S. branded market.
- No commercially relevant Phase 2 or Phase 3 development program is driving the molecule.
- Current research focuses on long-term consequences of prenatal exposure.
- The FDA warned against DES use during pregnancy in 1971.
- Core composition, formulation and manufacturing patent rights are long expired.
- No material current Paragraph IV litigation or settlement activity is associated with DES.
- Biosimilar risk is irrelevant because DES is a small-molecule estrogen, not a biologic.
- Market demand is fragmented across legacy, specialist, compounded and country-specific supply.
- Revenue is expected to remain negligible and flat to declining through 2030.
- The primary commercial risk is discontinuation or supply scarcity, not patent infringement.
FAQs
Is diethylstilbestrol still approved in the United States?
DES does not have a meaningful active U.S. branded market. Any current use is generally legacy, specialist, foreign-sourced or compounded and must be evaluated under the applicable regulatory framework.
Can a company still patent a new diethylstilbestrol product?
A company could seek patents on a genuinely novel formulation, delivery system or manufacturing process. It cannot recreate exclusivity over the old DES molecule itself.
Is diethylstilbestrol a biologic requiring biosimilar competition?
No. DES is a synthetic small-molecule estrogen. Generic-drug rules, not biosimilar pathways, are relevant.
Does DES have a future in prostate cancer treatment?
Its role is unlikely to expand. Modern androgen-deprivation and androgen-receptor therapies provide stronger clinical, regulatory and commercial support.
What is the main investment risk for a DES supplier?
The principal risk is insufficient demand to justify ongoing manufacturing, regulatory maintenance and active pharmaceutical ingredient sourcing. Patent competition is not the central risk.
References
Centers for Disease Control and Prevention. (n.d.). DES exposure: Questions and answers. https://www.cdc.gov/des/parents/
National Cancer Institute. (n.d.-a). Diethylstilbestrol (DES) exposure. https://dceg.cancer.gov/research/what-we-study/des
U.S. Food and Drug Administration. (1971). FDA drug bulletin: Diethylstilbestrol contraindicated in pregnancy. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-overview-eob
U.S. National Library of Medicine. (n.d.). Diethylstilbestrol. MedlinePlus. https://medlineplus.gov/druginfo/meds/a682704.html
